A la página anterior Volver a la pag. anterior

OSTEOGENESIS IMPERFECTA, TYPE I


Alternative titles; symbols
OI, TYPE I
OSTEOGENESIS IMPERFECTA TARDA
OSTEOGENESIS IMPERFECTA WITH BLUE SCLERAE



DESCRIPTION
The OI type I phenotype can be produced by mutation in either the COL1A1 gene (120150) or the COL1A2 gene (120160) and possibly in other genes. Osteogenesis imperfecta type I is a dominantly inherited, generalized connective tissue disorder characterized mainly by bone fragility and blue sclerae. In most cases, 'functional null' alleles of COL1A1 on chromosome 17 or COL1A2 on chromosome 7 lead to reduced amounts of normal collagen I.


CLINICAL FEATURES
Osteogenesis imperfecta (see Byers, 1993) is characterized chiefly by multiple bone fractures, usually resulting from minimal trauma. Affected individuals have blue sclerae, normal teeth, and normal or near-normal stature (for growth curves, see Vetter et al., 1992). Fractures are rare in the neonatal period; fracture tendency is constant from childhood to puberty, decreases thereafter, and often increases following menopause in women and after the sixth decade in men. Fractures heal rapidly with evidence of a good callus formation, and, with good orthopedic care, without deformity. Hearing loss of conductive or mixed type occurs in about 50% of families, beginning in the late teens and leading, gradually, to profound deafness, tinnitus, and vertigo by the end of the fourth to fifth decade. Additional clinical findings may be thin, easily bruised skin, moderate joint hypermobility and kyphoscoliosis, hernias, and arcus senilis. Mitral valve prolapse, aortic valvular insufficiency, and a slightly larger than normal aortic root diameter have been identified in some individuals (Hortop et al., 1986), but it is not clear that these disorders are significantly more frequent than in the general population.


Radiologically, wormian bones are common but bone morphology is generally normal at birth, although mild osteopenia and femoral bowing may be present. Vertebral body morphology in the adult is normal initially, but often develops the classic 'cod-fish' appearance (Steinmann et al., 1991).


EYES
Individuals with OI type I have distinctly blue sclerae which remain intensely blue throughout life, in contrast to the sclerae in OI type III and OI type IV which may also be blue at birth and during infancy. The intensity of the blue fades with time such that these individuals may have sclerae of normal hue by adolescence and adult life (Sillence et al., 1993). In a likely heterogeneous group of 16 patients with OI syndromes, Kaiser-Kupfer et al. (1981) found low ocular rigidity and small corneal diameter and globe length; no correlation was found between rigidity of the eyeball and blueness of the sclera. The central corneal thickness was found to be significantly lower in 53 patients with OI than that in 35 patients with otosclerosis and in 35 control subjects (Pedersen and Bramsen, 1984).


CARDIOVASCULAR
The prevalence and severity of cardiovascular involvement in OI type I was determined in a prospective study of patients of all ages (Pyeritz and Levin, 1981). Mitral valve prolapse occurred in 18% (3 times the prevalence in unaffected relatives) and rarely progressed to mitral regurgitation. Mean aortic root diameter was slightly but significantly increased and was associated with aortic regurgitation in 1 to 2%. No patient had suffered a dissection. Later, Hortop et al. (1986) studied 109 persons with nonlethal OI from 66 families. They could demonstrate no definite increase in the frequency of mitral valve prolapse over that to be expected in any group of persons. Aortic root dilatation was found by echocardiogram to be present in 8 of 66 persons with OI syndrome; dilatation was mild and unrelated to age of the patient but was strikingly aggregated in families. Of 109 persons surveyed, valvular disease was evident clinically in only 4 persons (aortic regurgitation in 2, aortic stenosis in one, and mitral valve prolapse in one). Hortop et al. (1986) stated that aortic root dilatation was seen in each of the different OI syndromes but strikingly segregated within certain families. They concluded that the mild and apparently nonprogressive nature of this lesion in OI argues against the use of beta-adrenergic blockade in affected individuals in the absence of systemic arterial hypertension.


EARS
In likely heterogenous groups of patients with OI, about half of affected individuals have hearing loss that begins during the second decade as a conductive loss; older individuals have sensorineural losses (Riedner et al., 1980; Pedersen, 1984). In only 1 major study was a majority of patients with sensorineural pattern observed (Shapiro et al., 1982). A female-to male-preponderance of 2:1 has been reported (Shea and Postma, 1982). Hearing loss is different from otosclerosis.


Clinical Variability
The disorder may exhibit considerable interfamilial and intrafamilial variability in the number of fractures and degree of disability. Rowe et al. (1985) reported a spectrum of disease severity within a 5-generation family. Those most severely affected exhibited more severe short stature and a mild degree of scoliosis relative to those who were less severely affected. Most striking were identical twins, the offspring of a mildly affected mother. Twin B was born small for gestational age, had had 12 fractures and was 150 cm tall (third centile) at 11 years of age. Her twin was born appropriate for gestational age and had had only 2 fractures at age 8 and 9 secondary to strenuous exercise; her current height was 162 cm (fiftieth centile). This family study suggested that the severity of the disease is roughly correlated with the reduction in collagen I synthesis.


Willing et al., 1990 described 5 affected individuals of a 3-generation family with marked clinical variability. They wondered if there might be subtle biochemical differences between the family members with respect to the amount of the abnormal pro-alpha-1(I) chains produced or their intracellular fate, but no differences were observed. They noticed that the more severely affected family members had children with both mild and severe phenotypes, while the mildly affected individual had an offspring with a mild phenotype. This suggested to them that there might be some other, not identified, factor segregating independently in this family that acts to modulate the final phenotype.


CLASSIFICATION
Using clinical, radiographic, and genetic criteria, Sillence et al. (1979) developed the classification currently in use into types I to IV: a dominant form with blue sclerae, type I (166200); a dominant form with normal sclerae, type IV (166220); a perinatally lethal OI syndrome, type II (166210); and a progressively deforming form with normal sclerae, type III (259420). The biochemical and linkage studies support the broad validity of the classification but confirm that it is incomplete. Although biochemical and genetic studies will provide the basis of the most rational classification, even such a detailed scheme probably will never predict correctly the evolution of OI in every affected individual, because of the still unexplained variability of expression seen in many families (Byers, 1993).


Bauze et al. (1975) divided their 42 patients with OI into mild, moderate, and severe groups according to deformity of long bones. None of the 17 patients in the mild group had scoliosis or white sclerae. The terms 'congenita' and 'tarda' now have limited usefulness, since they do not specify the mode of inheritance or basic biochemical defects.


It has been suggested that OI type I should be subdivided into type IA and IB on the basis of the absence or presence of dentinogenesis imperfecta (Levin et al., 1978). However, even mild dentinogenesis is uncommon among individuals with OI type I and has been observed in 4 out of 45 such individuals, and may be even more uncommon when the type of OI is defined by biochemical findings. Attempts to subdivide OI type I probably reflect the difficulty of distinguishing the blue sclerae in OI type I from the light blue-gray sclerae in individuals with OI type IV who most often have clinically apparent dentinogenesis imperfecta.


BIOCHEMICAL FEATURES
Byers (1993) summarized that 'functional null' alleles, i.e., silent alleles or mutations leading to excluded proteins, are the most common biochemical and genetic features of OI type I , although structural mutations in COL1A1 and COL1A2 leading to the synthesis of abnormal procollagen I can occasionally produce the OI type I phenotype.


Assessing reports of biochemical findings in the OI syndromes is difficult because the phenotype and genetics generally are not specified. Most studies deal, no doubt, with heterogeneous groups of patients. Several forms of OI were among the earliest of the inherited disorders of collagen biosynthesis and structure to be studied using cultured dermal fibroblasts from affected individuals (Martin et al., 1971; Penttinen et al., 1975). Cells cultured from patients who, in retrospect, would be considered to have OI type I, synthesized less procollagen I than did controls, but the mechanism by which production was decreased was not determined. These studies were extended from culture to tissue.


Francis et al. (1974) concluded that patients with OI and blue sclerae tend to have a reduced amount of collagen that has normal stability, as measured by resistance to depolymerization by pronase, heat, or cold alkali, whereas those with white sclerae have a normal amount of collagen with reduced stability; they suggested that a defect in cross-linking of collagen is present in the severe form of the disease.


Sykes et al. (1977) and, in a slightly extended study, Francis et al. (1981), found an increased ratio of collagen III to I in dermis and interpreted this as indicating a deficiency of collagen I. In studies of 44 patients with OI, Cetta et al. (1983) found in the largest category, the mild form, also an increased ratio of collagens III to I in skin and, in addition, an increased ratio of hydroxylysine diglycoside to monoglycoside in skin collagen.


Rowe et al. (1981) proposed that an additional criterion for OI type I is the production of a reduced quantity of collagen I. Among the cases of osteogenesis imperfecta with reduced synthesis of pro-alpha-1 chains, considerable heterogeneity is likely to emerge at the level of gene structure, as in the case of the globin genes in the thalassemias. Barsh et al. (1982) found that cultured skin fibroblasts from 3 patients produced half-normal levels of procollagen type I. Furthermore, the OI cells contained equimolar amounts of pro-alpha-1(I) and pro-alpha-2(I) chains, which suggested that trimer assembly and secretion were limited by the level of pro-alpha-1(I) chain synthesis. The 'extra' pro-alpha-2(I) chain in the OI cells was in a non-disulfide bonded configuration and apparently contributed to an increased level of intracellular degradation. The results of Barsh et al. (1982) suggested that the stoichiometry of the pro-alpha chains in procollagen I is determined by the conformation of the chains rather than by the ratio in which they are synthesized, that molecules containing more than a single pro-alpha-2(I) chain are not assembled, and that the production of collagen I can be regulated by controlling synthesis of only one of its subunits.


Rowe et al. (1985) demonstrated that reductions in collagen I production and in the ratio of alpha-1(I) to alpha-2(I) mRNA are clearly segregated with affected individuals within the 5 generation family. Rowe et al. (1985) further suggested that the severity of the disorder is roughly correlated with the reduction in collagen I synthesis.


Wenstrup et al. (1990) correlated clinical severity in nonlethal variants of OI with the nature of the alteration in the alpha chains of procollagen I secreted by cultured fibroblasts. Cells from 40 probands secreted about half the normal amount of normal procollagen I and no identifiable abnormal molecules; these patients were generally of normal stature, rarely had bone deformity or dentinogenesis imperfecta, and had blue sclerae. Cells from 74 other probands produced and secreted normal and abnormal procollagen I molecules; these patients were usually short and had bone deformity and dentinogenesis imperfecta, and many had gray or blue-gray sclerae. In cells from yet another 18 probands, Wenstrup et al. (1990) were unable to identify altered procollagen I synthesis or structure.


OTHER FEATURES
Dickson et al. (1975) reported a quantitative and qualitative abnormality of noncollagenous proteins of bone. Lancaster et al. (1975) found a consistent morphologic abnormality of cultured skin fibroblasts: irregular packing of aggregated cells and an irregular tessellated appearance of individual fibroblasts. Boright et al. (1984) showed that dermal fibroblasts derived from individuals with OI type I take longer than control cells to reach confluency, have a lower cell density at stationary phase and have an abnormal cell shape as judged by the increased ratio of width to length. An increase in population doubling time of fibroblasts derived from individuals with the milder form of OI was also observed by Rowe and Shapiro (1982).


INHERITANCE
The mode of inheritance is autosomal dominant. Penetrance of blue sclerae is 100 percent, while penetrance of hearing loss is clearly age-dependent (Garretsen and Cremers, 1991). Paternal age effect for increased risk of new mutations has been documented although it appears to be considerably lower than, for example, in achondroplasia (100800). In 10 cases with OI type I presumed to have arisen by new mutation, the mean paternal age was increased by 2.1 years (Sillence et al., 1979), whereas in 38 other cases it was significantly increased by 2.9 years (Carothers et al., 1986).


MAPPING
In all but 1 of 11 families with OI tarda, Sykes et al. (1986) found that the disorder segregated with either the COL1A1 locus or the COL1A2 locus. In 1 small family, segregation occurred with both genes, but this disorder clearly cannot be linked to both; had further meioses been available, the OI gene would probably have segregated independently of at least 1 of the 2 loci. Tsipouras (1987), also, concluded that mild OI is genetically heterogeneous and that 1 or more loci other than COL1A1 and COL1A2 may be involved in the causation of phenotypically indistinguishable autosomal dominant OI.


Sykes et al. (1990) studied segregation of the COL1A1 and COL1A2 genes in 38 dominant osteogenesis imperfecta pedigrees. None of the 38 pedigrees showed recombination between the OI gene and both collagen loci. All 8 pedigrees with OI type IV (166220) segregated with COL1A2. On the other hand, 17 type I pedigrees segregated with COL1A1 and 7 with COL1A2. The concordant locus was uncertain in the remaining 6 OI type I pedigrees. The presence or absence of presenile hearing loss was the best predictor of the mutant locus in OI type I families, with 13 of the 17 COL1A1 segregants and none of the 7 COL1A2 segregants showing this feature. By linkage analysis in 7 autosomal dominant osteogenesis imperfecta families in Italy, Mottes et al. (1990) showed that the COL1A1 gene was implicated in 2 families and the COL1A2 gene in 1 family with OI type I. The COL1A2 gene was implicated in 2 families with OI type IV. In 2 OI type I families, the molecular genetic data were insufficient for exclusion of one gene.


MOLECULAR GENETICS
Byers (1993) summarized that 'functional null' alleles are the most common genetic features of OI type I. The mechanism by which the synthesis of pro-alpha-1(I) chains is decreased remains a difficult problem to solve. A variety of mutations, such as deletion of an allele, promoter and enhancer mutations, splicing mutations, premature termination, as well as other mutations that result in the inability of pro-alpha-1(I) chains to assemble into molecules, would presumably result in the same biochemical picture and the same phenotype. In some individuals, the decreased production of pro-alpha-1(I) chains by fibroblasts results from about half-normal steady-state levels of the mRNA (Rowe et al., 1985). Later studies on these cells indicated that there is a defect in splicing of the pre-mRNA of COL1A1 that prohibits transport of the product of the mutant allele to the cytoplasm; the ratio of pro-alpha-1(I) to pro-alpha-2(I) mRNA was 1:1 in the cytoplasm instead of the normal 2:1, whereas the ratio was 4:1 in the nucleus instead of the normal 2:1 (Genovese and Rowe, 1987). Furthermore, a novel species of alpha-1(I) mRNA present in the nuclear compartment was not collinear with a cDNA probe (Genovese et al., 1989). In another individual with OI type I, Stover et al. (1993) demonstrated a G-A transition in the first position of the splice donor site of intron 26 which resulted in inclusion of the entire succeeding intron in the mature mRNA that accumulated in the nuclear compartment; apparently because no abnormal pro-alpha-1(I) chains were synthesized from the mutant allele, the clinical phenotype of this individual was mild. In a large study, Willing et al. (1992) showed that among 70 individuals with OI type I 23 from 21 families were heterozygous at the COL1A1 polymorphic MnlI site. As shown by primer extension with nucleotide-specific chain termination, there was in each case marked diminution in steady-state mRNA levels from one COL1A1 allele. Loss of an allele through deletion or rearrangement was not the cause of the diminished COL1A1 mRNA levels. Only in one family has the causative mutation been identified; an A-G transition in the obligatory acceptor splice site of intron 16 resulted in skipping of exon 17 in the mRNA which represented only 10% of the total COL1A1 mRNA. Further, linkage studies in 38 additional families have demonstrated no evidence of deletion of those regions of the COL1A1 gene used for linkage analysis (Sykes et al., 1986, 1990) and confirmed that most individuals with the OI type I phenotype have mutations linked to the COL1A1 gene. In some families, a similar phenotype is thought to result from mutations in the COL1A2 gene (Sykes et al., 1986, 1990; Wallis et al., 1986), but the clinical criteria by which the diagnosis of OI type I is made are not always clear. Willing et al. (1990) described a 5-bp deletion near the 3-prime end of one COL1A1 allele that resulted in a reading frame shift 12 amino acid residues from the normal terminus of the chain and predicted an extension of 84 amino acid residues beyond the normal termination site. Although the abnormal mRNA could be translated in vitro, it proved extremely difficult to identify the abnormal chains in cells; it appeared that although the mRNA was present in normal amount, the protein product was unstable. This mutation provides a model of how many different mutations in the COL1A1 gene could produce the OI type I phenotype by resulting in the synthesis of half the normal amount of a functional pro-alpha-1(I) chain.


In an effort to further understand the reasons for diminished COL1A1 transcript levels in OI type I, Willing et al. (1995) investigated whether mutations involving key regulatory sequences in the COL1A1 promoter, such as the TATAAA and CCAAAT boxes, are responsible for the reduced levels of mRNA. They used PCR-amplified genomic DNA in conjunction with denaturing gradient gel electrophoresis and SSCP to screen the 5-prime untranslated domain, exon 1, and a small portion of intron 1 of the COL1A1 gene. In addition, direct sequence analysis was performed on an amplified genomic DNA fragment that included the TATAAA and CCAAAT boxes. In a survey of 40 unrelated probands with OI type I in whom no causative mutation was known, Willing et al. (1995) identified no mutations in the promoter region and there was 'little evidence of sequence diversity among any of the 40 subjects.'


Although less common than 'functional null' allele mutations, there are several examples in which the synthesis of abnormal procollagen I molecules can produce the OI type I phenotype. In one family (Nicholls et al., 1984), cells cultured from the affected mother and son, but not those from the normal daughter, synthesized alpha-1(I)-chains bearing a cysteine residue within the protease-resistant domain of the collagen molecule, a region from which that residue is normally absent. Although it was initially thought that the cysteine substitution was at the X or Y position of the Gly-X-Y repeating unit of the alpha-1(I) chain in the carboxyl-terminal peptide CB6 (Steinmann et al., 1986), peptide sequence analysis and sequencing of the cDNA demonstrated that the mutation resulted in the substitution of a glycine by cysteine in position 1017 in the telopeptide, 3 amino acid residues from the carboxy-terminal to the end of the triple helix (Cohn et al., 1988; Labhard et al., 1988).


Other substitutions of cysteine for glycine within the triple helical domain of the alpha-1(I) chain at residue 94 (Starman et al., 1989; Byers, 1993; Shapiro et al., 1992; Nicholls et al., 1990) also produce mild forms of OI, perhaps compatible with OI type I. Byers et al. (1983) described an isolated patient with a mild-to-moderate form of OI: blue sclerae, a height of 147 cm, deformity as a consequence of poor orthopedic treatment, and hearing loss. Her cells synthesized a pro-alpha-2(I) chain in which approximately 30 amino acid residues were deleted from the triple-helical domain, in the CB4 peptide, a domain in which phosphoproteins important to bone calcification may bind and in which crosslinks may form. Subsequent studies indicated that a point mutation at the consensus splice-donor site resulted in the skipping of exon 12 (amino acids 91-108) from about half the COL1A2 transcripts (Rowe et al., 1990). Zhuang et al. (1993) showed that deletion of 19 bp from +4 to +22 of intron 13 of COL1A2 caused skipping of exon 13 in about 88% of the transcripts, whereas 12% of the transcripts were normally spliced; procollagen I containing the mutated pro-alpha-2(I) chain had reduced thermal stability and was only poorly secreted from the cells.


A woman with 'postmenopausal osteoporosis' was reported by Spotila et al. (1991) to be heterozygous for a serine-to glycine substitution at position 661 of the alpha-2(I) triple-helical domain. Since her 3 sons, who inherited the mutation, had experienced fractures as adolescents, the diagnosis of 'mild OI cannot be fully excluded' according to the authors' view; one of the sons was homozygous for the mutation due to partial isodisomy for maternal chromosome 7 (Spotila et al., 1992). All these findings suggest that other point mutations in the COL1A1 gene, and perhaps in the COL1A2 gene (as suggested also by linkage studies), could lead to a phenotype similar to that produced by 'functional null' allele mutations.


DIAGNOSIS
The diagnosis is based on clinical and genetic criteria. In sporadic cases, the diagnosis may be difficult, and secondary osteoporosis and nonaccidental injury has to be ruled out. In women with severe 'postmenopausal osteoporosis' careful clinical investigation and a thorough personal and family history quite often reveals OI type I. While the direct molecular characterization is not feasible in the majority of cases at present, demonstration of reduced synthesis of procollagen I by dermal fibroblasts is indicative for the disorder. Lynch et al. (1991) discussed the problem of making the prenatal diagnosis of OI type I on the basis of linkage.


CLINICAL MANAGEMENT
No medical treatment for OI type I is known that decreases the frequency of bone fracture or increases bone density; an effective agent would have to increase the production of procollagen I, if the mutation resulted in diminished synthesis and secretion. Apparent success can be attributed to the natural history of OI, with spontaneous reduction in the fracture rate with increasing age and/or to placebo effect.


Bembi et al. (1997) described the results of treatment of 3 children with OI type I with cyclic intravenous infusions of aminohydroxypropylidene bisphosphonate (pamidronate). Each of the children had repeated bone fractures and low bone density. The rationale for pamidronate therapy in OI is based on the fact that bisphosphonates inhibit osteoclastic bone resorption; this leads to increased bone density and possibly to reduced risk of fracture. Bembi et al. (1997) reported a clear clinical response over the 22- to 29-month treatments, with a striking reduction in the frequency of new fractures. They also observed an effect on bone density. There were no notable adverse effects during therapy.


In an uncontrolled observational study involving 30 children aged 3 to 16 years with severe osteogenesis imperfecta, Glorieux et al. (1998) administered pamidronate intravenously at 4- to 6-month intervals for 1.3 to 5.0 years. They observed a sustained reduction in serum alkaline phosphatase concentrations and in the urinary excretion of calcium and type I collagen N-telopeptide. Increases in the size of the vertebral bodies suggested that new bone had formed. The mean incidence of radiologically confirmed fractures decreased by 1.7 per year (P less than 0.001). Treatment with pamidronate did not alter the rate of fracture healing, the growth rate, or the appearance of growth plates. Mobility and ambulation improved in 16 children and remained unchanged in the other 14. Marini (1998) commented that fluoride and calcitonin treatment in OI had proved unsuccessful. The bisphosphonates are synthetic analogs of pyrophosphate, a natural inhibitor of osteoclastic bone resorption. They have been useful in the treatment of osteoporosis, Paget disease of bone, and fibrous dysplasia. The children with severe osteogenesis imperfecta treated by Glorieux et al. (1998) fell into the type III (259420) and type IV (166220) categories of osteogenesis imperfecta.


Fractures in OI are treated with standard orthopedic procedures appropriate for the type of fracture and the age, and heal rapidly with evidence of good callus formation (sometimes with hypertrophic callus formation) and without deformity. Regular hearing evaluations after adolescence and early stapedectomy or stapedotomy are recommended. In postmenopausal women with OI, a long-term physical therapy program to strengthen the paraspinal muscles, together with estrogen and progesterone replacement, adequate calcium intake, and perhaps calcitonin or fluoride administration, may be specifically indicated (for review, see Steinmann et al., 1990).


POPULATION GENETICS
In the county of Fyn, where approximately 9% of the Danish population lives, Andersen and Hauge (1989) identified 48 patients with osteogenesis imperfecta, of whom 17 were born between January 1, 1970 and December 31, 1983. Of the 17, 12 had type I, 2 had type II, 2 had type III, and 1 had type IV. The point prevalence at birth was 21.8/100,000 and the population prevalence was 10.6/100,000 inhabitants. All ethnic and racial groups seem to be similarly affected (Byers, 1993).


ANIMAL MODEL
Bonadio et al. (1990) reported that the heterozygous Mov-13 mouse, which has a murine retrovirus integrated within the first intron of the COL1A1 gene, is a good model for the mild autosomal dominant form of OI. The animals showed morphologic and functional defects in mineralized and nonmineralized connective tissue and progressive hearing loss.

 Pincha aquí para subir